Thrombostatins are a group of compounds based upon a breakdown product of bradykinin, RPPGF. They inhibit -thrombin-induced platelet activation by binding to protease activated receptor 1 and, at a lower affinity, by interacting with thrombin’s active site. After a single intravenous infusion of MAP4-RPPGF (11.58 mg/kg), its t½α was 4.5 min with a clearance of 2.0 ml/min. MAP4-RPPGF administration had a sustained antiplatelet effect, preventing γ-thrombin-induced (12.5 nM) platelet activation for 4 h. Its antiplatelet effect summated with that of aspirin and/or clopidogrel. MAP4-RPPGF was compared with aspirin and clopidogrel in the Folts model of coronary artery thrombosis. Dogs were randomized to 3 treatment groups: aspirin 1.14 mg/kg i. v., clopidogrel 0.5 mg/kg i. v., or MAP4-RPPGF 0.77 mg/kg i. v. Cyclic flow variations (CFV) were recorded in 5 untreated dogs hourly for 3 successive hours and for 1 h before (all groups >11 CFV/h), and for 2 h after drug infusion in each of the 3 treatment groups. After 1 h drug treatment, all groups of animals had <6 CFV/h; after 2 h treatment, all had <1 CFV/h. All agents significantly reduced CFV from control at each hour, but none was significantly better than any other. Thrombostatin was as effective as aspirin or clopidogrel in inhibiting coronary artery thrombosis in this canine model.
1
Shima C,
Majima M,
Katori M.
A stable metabolite, Arg-Pro-Pro-Gly-Phe, of bradykinin in the degradation pathway in human plasma. Jpn J Pharmacol 1992; 60: 111-9.
2
Majima M,
Sunahara N,
Harada Y,
Katori M.
Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem Pharmacol 1993; 45: 559-67.
4
Jiang Y,
Muller-Esterl W,
Schmaier A.
Domain 3 of kininogen contains a cell binding site and a site that modifies thrombin activation of platelets. J Biol Chem 1992; 267: 3712-7.
5
Hasan A,
Amenta S,
Schmaier A.
Bradykinin and its metabolite, Arg-ProPro-Gly-Phe, are selective inhibitors of alpha-thrombin-induced platelet activation. Circulation 1996; 94: 517-28.
6
Puri R,
Zhou F,
Hu C-J,
Colman R,
Colman R.
High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood 1991; 77: 500-7.
10
Folts J,
Rose G.
Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thrombosis Research 1988; 50: 507-16.
12
Folts J,
Schafer A,
Loscalzo J,
Willerson J,
Muller J.
A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 1999; 33: 295-303.
18
Coller B,
Folts J,
Scudder L,
Smith S.
Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood 1986; 68: 783-6.
19
Yao S-K,
Ober J,
McNatt J,
Benedict C,
Rosolowky M,
Anderson H,
Cui K,
Maffrand J,
Campbell W,
Buja L,
Willerson J.
ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res 1992; 70: 39-48.
22
Eichhorn E,
Grayburn P,
Willard J,
Anderson H,
Bedotto J,
Carry M,
Kahn J,
Willerson J.
Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol 1991; 17: 43-52.
23
Anderson H,
Kirkeeide R,
Krishnaswami A,
Weigelt L,
Revana M,
Weisman H,
Willerson J.
Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994; 23: 1031-7.
